View Press Releases
Sygnature Discovery strengthens in vivo pharmacology leadership with appointment of Susanne Back
Sygnature Discovery strengthens in vivo pharmacology leadership with appointment of Susanne Back
Nottingham, UK - 25 March 2026 – Sygnature Discovery, a leading integrated drug discovery contract research organisation (CRO), has announced the appointment of Susanne Back as Head of In Vivo Pharmacology, further strengthening its bioscience leadership and reinforcing its commitment to delivering high-quality, integrated drug discovery solutions for customers worldwide.
Susanne brings 20 years of in vivo pharmacology experience across academia and industry, including senior scientific and leadership roles at Orion Pharma and Charles River. Based in Nottingham, she will lead one of Sygnature’s in vivo pharmacology teams, overseeing approximately 30 scientists and working closely with multidisciplinary project teams and clients to deliver robust in vivo strategies that support informed decision-making across drug discovery programmes.
In her role, Susanne will be responsible for the scientific and operational leadership of the team, including resource planning, workflow optimisation, and the continued development of innovative and competitive in vivo capabilities. She will also provide expert input into study design and act as a key scientific and operational point of contact for clients.
Commenting on her appointment, Susanne Back said: “I was particularly attracted to Sygnature because of its world-leading integrated drug discovery expertise and the calibre of its scientific community.
“The co-located, multidisciplinary environment creates a truly collaborative setting where complex discovery challenges can be addressed efficiently. I am looking forward to working closely with colleagues and clients to ensure we continue to deliver translational in vivo data that accelerates drug discovery programmes.”
Fraser McIntosh, VP of in vivo pharmacology at Sygnature Discovery added: “Susanne brings deep scientific expertise in in vivo pharmacology alongside a strong track record of leading high-performing teams in complex discovery environments. Her ability to translate project objectives into well-designed in vivo strategies will be instrumental in strengthening our integrated offering and ensuring we continue to deliver high-quality, decision-enabling data for our customers.”
Looking ahead, Susanne aims to establish a clear scientific and operational strategy for the in vivo pharmacology function, while strengthening cross-functional alignment and building strong internal and client relationships to support long-term business success.
Sygnature Discovery recently announced a strategic brand relaunch, including a new website, reinforcing its position as a global drug discovery partner. Building on more than 20 years of growth, investment and targeted acquisitions, the company now offers fully integrated Design, Make, Test, Analyze (DMTA) capabilities under one roof across both Europe and North America.
With expertise spanning bioscience, medicinal and synthetic chemistry, protein science and structural biology, DMPK, in vivo pharmacology, computer-aided drug design, and form and formulation, Sygnature’s co-located, multidisciplinary teams — supported by AI and automation — are designed to help biotech and pharma companies accelerate decision-making and advance high-quality drug candidates more efficiently.
ENDS
About Sygnature Discovery
At Sygnature Discovery, we create exceptional scientific outcomes. For our customers, who bring life-changing medicines to patients; and for our people, who help make this possible.
We’re 700+ scientists from over 50 countries, working as one across Europe and North America. With no competing internal programs, we offer total confidentiality and commitment.
Over the past 20+ years, we’ve earned a track record of real impact: 60+ advanced candidates, 200+ patents filed, 200+ active projects. Over 90% of our customers choose to stay with us – from biotechs racing to clinic to pharma companies that need specialised expertise for targeted challenges.
Media Contact
rachael@ramarketingpr.com